During the corresponding time, Angiodynamics Inc recorded a revenue increase by 8.05 % year on year, sequentially revenue grew by 11.78 %. While revenue at the Angiodynamics Inc 's corporate clients
Angiodynamics Inc's Comment on Sales, Marketing and Customers
AngioDynamics provides medical products primarily for interventional radiology and peripheral arterial disease treatment. Their product portfolio includes diagnostic catheters for non-coronary angiography, thrombolytic delivery systems, ablation and NanoKnife systems, vascular access products, angiographic products and accessories, dialysis products, drainage products, thrombolytic products, embolization products, and venous products. The Auryon Atherectomy System is designed to treat peripheral arterial disease and supports multiple access points, including femoral, pedal, and radial, enabling expanded treatment options. The company has expanded its offerings through acquisitions of various companies and product lines in these medical segments. Customers and markets associated with AngioDynamics include Clinical Devices, Diomed, Eximo Medical, Ltd., Medical Components Inc., Medline Industries, Inc., Merit Medical Systems, Inc., Microsulis Medical Limited, Navilyst Medical, Oncobionic, QX Medical, LLC, RadiaDyne, RITA Medical Systems, Spectrum Vascular, Surgical Specialties, LLC, and Vortex Medical, Inc.
LATHAM, N.Y. AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company, has announced a significant milestone in its ongoing efforts to advance the treatment of vascular diseases and improve patient outcomes. The AlphaVac F1885 System has received European CE Mark approval, signifying its compliance with stringent European health, safety, and environmental protection standards. This achievement underscores the system’s potential as a transformative tool for the non-surgical removal of thrombi or emboli from the pulmonary arteries, specifically for the treatment of pulmonary embolism (PE). CE Mark Approval: A Game-Changer for Pulmonary Embolism TreatmentThe CE Mark appro...
LATHAM, N.Y. AngioDynamics, Inc. (NASDAQ: ANGO), a pioneering medical technology company committed to transforming vascular health, broadening cancer treatment options, and enhancing patient quality of life, has proudly announced the European CE Mark approval of its AlphaVac F18 System. This revolutionary development paves the way for the non-surgical removal of thrombi or emboli from the pulmonary arteries and the treatment of pulmonary embolism (PE). A Game-Changer in Vascular Health The CE Mark approval is a significant milestone for AngioDynamics, underscoring their continuous commitment to developing cutting-edge technologies aimed at improving vascular health. Pulmonary Embolism (PE) is a life-threat...
Pulmonary embolism (PE) is a serious medical condition characterized by a sudden blockage in one of the arteries in the lungs. If left untreated, PE can be life-threatening. Current treatment options for PE include medication to prevent further blood clots and procedures such as thrombectomy to remove the clot. However, these procedures can be invasive and carry risks.The APEX-AV trial aimed to assess the efficacy and safety of AngioDynamics AlphaVac F18 System in the treatment of PE. The AlphaVac F18 System is a minimally invasive device designed to extract blood clots from the pulmonary arteries using vacuum technology. The trial involved 100 patients with acute PE who were treated with the AlphaVac F18 S...
Angiodynamics Inc’s Comment on Sales, Marketing and Customers
AngioDynamics provides medical products primarily for interventional radiology and peripheral arterial disease treatment. Their product portfolio includes diagnostic catheters for non-coronary angiography, thrombolytic delivery systems, ablation and NanoKnife systems, vascular access products, angiographic products and accessories, dialysis products, drainage products, thrombolytic products, embolization products, and venous products. The Auryon Atherectomy System is designed to treat peripheral arterial disease and supports multiple access points, including femoral, pedal, and radial, enabling expanded treatment options. The company has expanded its offerings through acquisitions of various companies and product lines in these medical segments. Customers and markets associated with AngioDynamics include Clinical Devices, Diomed, Eximo Medical, Ltd., Medical Components Inc., Medline Industries, Inc., Merit Medical Systems, Inc., Microsulis Medical Limited, Navilyst Medical, Oncobionic, QX Medical, LLC, RadiaDyne, RITA Medical Systems, Spectrum Vascular, Surgical Specialties, LLC, and Vortex Medical, Inc.
Sources:
Angiodynamics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Angiodynamics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Angiodynamics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
173.14 %